NR1H4 and diabetes mellitus: In addition, INT-747, PX-102 and WAY-362450 are synthetic FXR agonists that are currently under development for treating dyslipidemia, diabetes, primary biliary cirrhosis or NASH, but safety issue remains a major concern for these synthetic molecules.